CD4+/CD56+ hematodermic neoplasm

MONDO:0019467

An aggressive immature hematologic neoplasm formerly known as blastic NK cell lymphoma, composed of cells with a lymphoblast-like morphology. Recent evidence suggests derivation from a plasmacytoid monocyte. Patients present with cutaneous tumors and bone marrow involvement.

Also known as: BPDCN, CD4+/CD56+ hematodermic neoplasm, agranular CD4+ CD56+ hematodermic neoplasm/tumor, agranular CD4+ natural Killer cell leukaemia, agranular CD4+ natural Killer cell leukemia, blastic NK-cell lymphoma, blastic natural Killer leukemia/lymphoma, blastic plasmacytoid Dendritic cell neoplasm

3160 clinical trials for this condition and its sub-types, 31 tagged with CD4+/CD56+ hematodermic neoplasm itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Myeloid neoplasm (2708) ↑ Skin cancer (801) ↑ T-cell non-Hodgkin lymphoma (410)

Including sub-types (3160) Tagged with CD4+/CD56+ hematodermic neoplasm (31)

Trials to join now! 12 Not yet recruiting 1 Not yet finished but already full! 7 Completed 6 Terminated 5

Tweaking donor cells may shield older transplant patients from a dangerous complication

Prevention Not yet recruiting

Researchers are testing whether removing a specific type of immune cell, called CD45RA-positive naive T cells, from donor stem cells can prevent graft-versus-host disease in older adults undergoing stem cell transplants for acute leukemia or myelodysplastic syndrome. The trial en…

Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention

Last updated Sep 16, 2026 00:00 UTC

CD4+/CD56+ hematodermic neoplasm

Where it sits in the disease tree

Tweaking donor cells may shield older transplant patients from a dangerous complication